Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05489120
Other study ID # EFFLAVIS
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date November 6, 2022
Est. completion date September 15, 2025

Study information

Verified date September 2023
Source Dr. Schär AG / SPA
Contact Charlotte Cameli
Phone 0299121962
Email c.cameli@slbpharma.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The KDOQI 2020 - Clinical practice guideline for nutrition in chronic kidney disease (CKD) -recommends protein restriction to reduce the risk of end-stage renal disease/death and improve quality of life, a low protein diet providing 0.55-0.60g dietary protein/ kg body weight/day is recommended. FLAVIS® is a product line of hypoprotein foods specially developed for the treatment of CKD.The use of low-protein foods may facilitate the achievement of nutritional goals in terms of protein intake and help patients to follow a low-protein diet.


Recruitment information / eligibility

Status Recruiting
Enrollment 244
Est. completion date September 15, 2025
Est. primary completion date September 15, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - CKD patient stage 3b-5 (<45 ml/min/1.73 m² estimated by CKD-EPI formula) and not on dialysis, - With a good nutritional status (i.e., absence of malnutrition according to albumin, pre-albumine, BMI and no clinical and paraclinical criteria of malnutrition), - Above 1g protein/ kg bw (ideal body weight), - LPD-naïve patient, - Motivated to LPD introduction (ensure during screening phase patient willingness to modify diet habits with counselling accurate follow-up), - Available to attend the visits planned by the protocol and able to complete the data collection documents (diet record and self-administered questionnaires), - Subject affiliated to a health insurance system or is a beneficiary (art. L.1121-11, Code of Public Health, France), - Having given their informed written consent regarding its participation to the protocol. Exclusion Criteria: - Patient for whom dialysis or transplantation is planned/expected within the next 12 months - Known allergic reactions to the ingredients present in FLAVIS products (milk, eggs, soy, nut), - Diabetis mellitus (Type I and 2 defined as fasted glycemia > 1 .26 g/L or HbA1C >7% or anti-diabetic treatment), - Active cancer, - Psychiatric disorders or inability to follow the protocol, - Evidence of any active infectious or inflammatory diseases, - Inability to provide blood samples (poor venous capital), - Inability to perform correct 24-hours urine collection, - Any change of the chronic medication within 1 month before screening, - Presence of any significant medical finding or significant history such as uncontrolled systemic diseases that may impact the safety, the interpretation of the results and/or the participation of the subject in the study according to the opinion of the investigator, - Simultaneous participation in another clinical trial or subject still within the exclusion period of a previous clinical trial. - Vulnerable subjects (art. L. 1121-5 à 8 et L. 1122-1-2, Code of Public Health, France) are also excluded from the clinical trial.

Study Design


Intervention

Other:
Consumption of FLAVIS
Patients of the FLAVIS group will recevied FLAVIS products in addition to their diet follow-up.

Locations

Country Name City State
France Cabinet médical du Dr Magnant Aix-en-Provence
France CHU Besançon Besançon
France Maison du Rein Bordeaux
France CH Chalon Chalon-sur-Saône
France CHU Gabriel Montpied Clermont-Ferrand
France CH Le Mans Le Mans
France Hospices Civiles de Lyon Lyon
France CH Mâcon Mâcon
France Hôpital la conception Marseille
France AURA Paris Paris
France Tenon hospital -APHP Paris
France Hôpital Nord-Ouest Villefranche-sur-Saône

Sponsors (2)

Lead Sponsor Collaborator
Dr. Schär AG / SPA Slb Pharma

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Effectiveness in terms of protein intake of a LPD with LP foods (FLAVIS products) compared to standard products (LPD without consumption of LP foods) Maroni formula : (Measurement of urea in urine + ([patient weight]*0.031))*6.25 12 month
Secondary Protein intake during the 12 months follow-up Maroni formula: (Measurement of urea in urine + ([patient weight]*0.031))*6.25 1 month, 3 month, 6 month and 9 month
Secondary Dietary adherence 3-day dietary record correlated to a 24-hour urine collection baseline, 1 month, 3 month, 6 month and 12 month
Secondary Dietary compliance for products under study quantities consumed of FLAVIS products. monthly up to 12 months
Secondary Effects of the LPD on BMI weight and height will be combined to report BMI in kg/m^2 baseline, 1 month, 3 month, 6 month and 12 month
Secondary Effects of the LPD on weight Weight in kg baseline, 1 month, 3 month, 6 month and 12 month
Secondary Effects of the LPD on body composition: water Water in litres baseline, 1 month, 3 month, 6 month and 12 month
Secondary Effects of the LPD on body composition: muscles Muscles in Kg baseline, 1 month, 3 month, 6 month and 12 month
Secondary Effects of the LPD on body composition: body protein content Body protein content in Kg baseline, 1 month, 3 month, 6 month and 12 month
Secondary Effects of the LPD on Blood Blood Chemistry baseline, 1 month, 3 month, 6 month, 9 month and 12 month
Secondary Effects of the LPD on Urine Urine Chemistry baseline, 1 month, 3 month, 6 month, 9 month and 12 month
Secondary Incidence of Adverse Events [Safety of the LPD] Questioning and a clinical examination; 4-point Likert scale. 3 month, 6 month and 12 month
Secondary Patient quality of life SF-36 questionnaire score which from 0 to 100 baseline, 3 month, 6 month and 12 month
Secondary Patient satisfaction with LPD Auto-questionnaire, open questions 3 month, 6 month and 12 month
See also
  Status Clinical Trial Phase
Terminated NCT03539861 - Immunomodulatory Biomimetic Device to Treat Myocardial Stunning in End-stage Renal Disease Patients N/A
Recruiting NCT03311321 - Vitamin K to Slow Progression of Cardiovascular Disease Risk in Hemodialysis Patients N/A
Completed NCT05630729 - Living With CKD: An E-Learning Platform for Adolescents With CKD About the Disease and Its Management N/A
Withdrawn NCT03998917 - Pathophysiological Characterization of the Neuromuscular Function of a Population With Multiple Comorbidities Suffering From Chronic Renal Failure in Pre-dialysis.
Completed NCT04207203 - Healthy Diet Rich in Potassium to Chronic Kidney Disease With Sodium Zirconium Cyclosilicate: A Feasibility Study N/A
Recruiting NCT01591876 - Exercise and Vascular Function in Haemodialysis Patients Phase 2
Not yet recruiting NCT04608422 - Bioeletric Stimulation in Patients With Chronic Kidney Failure N/A
Completed NCT03868371 - Acute Changes in the Mineral Metabolism After a High Phosphorous Containing Meal in Dialysis Patients N/A
Active, not recruiting NCT05225454 - The Life Style Patterns and the Development Trend of Chronic Diseases in Healthy and Sub-healthy Groups Were Analyzed by Using Data-mining Techniques
Completed NCT03459807 - Blood Pressure Lowering in Dialysis (BOLD) Trial Phase 2
Not yet recruiting NCT03005847 - The Effect of Fermented Papaya Preparation on Patients With Chronic Kidney Disease Under Dialysis Receiving Intravenous Iron N/A
Recruiting NCT05726526 - CKD Specific Telemonitoring Platform to Minimize Adverse Outcomes in High Risk CKD Patients N/A
Recruiting NCT04330807 - Physiopathology of Neuromuscular Function Related to Fatigue in Chronic Renal Disease N/A
Active, not recruiting NCT02858778 - Timing of Acute Palliative Care Consultation in Critically Ill Patients N/A
Active, not recruiting NCT04034966 - Utility of Telemedicine in the Follow-Up of Patients in Peritoneal Dialysis N/A
Completed NCT04012957 - Desidustat in the Treatment of Anemia in CKD Phase 3
Terminated NCT02039167 - Left Atrial Appendage Occlusion vs. Usual Care in Patients With Atrial Fibrillation and Severe Chronic Kidney Disease N/A
Completed NCT01764854 - Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on Hemodialysis Phase 2
Active, not recruiting NCT06037265 - PR-0164 First in Human Clinical Trial of the PAVmed PortIO Intraosseous Infusion System N/A
Active, not recruiting NCT05350098 - Efficacy of Plant-protein Diets in Patients With Chronic Kidney Disease N/A